Rana R. McKay, MD

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes. 

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Rana R. McKay, MD, discusses adapting treatment for patients with cancer during the coronavirus disease 2019 pandemic.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).